Experts agree that the urological cancer patient will benefit greatly if the delivered treatment is the result of a combined effort. Collaboration of experts from various fields is, therefore, necessary to take cancer-related research and medical practice to the next level.

CNSBio Inc. will present recent Phase IIa proof-of-concept clinical trial data for CNSB015, an orally administered potassium channel modulator used in combination with opioids for the treatment of neuropathic pain, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain on November 20-21, 2009 in San Francisco, CA. Dr.

Most heart failure patients who develop kidney failure in the hospital do not recover from it before going home and are at increased risk of either being re-hospitalized or dying within the year, according to a Henry Ford Hospital study. The study's gloomy finding is the first time researchers linked long-term health outcomes with declining kidney function in patients hospitalized for heart failure.

Seattle Genetics, Inc. (Nasdaq: SGEN) announced that it has initiated a phase I clinical trial of SGN-75 for metastatic renal cell carcinoma and relapsed and refractory non-Hodgkin lymphoma. SGN-75 is an antibody-drug conjugate (ADC) targeting CD70 that utilizes the company's proprietary technology.

Risk of bladder cancer for smokers has increased since the mid-1990s, with a risk progressively increasing to a level five times higher among current smokers in New Hampshire than that among nonsmokers in 2001-2004, according to a new study published online November 16 in the Journal of the National Cancer Institute.